Evexta Bio

Evexta Bio Announces the Appointment of Paul Gineste, PharmD, as Chief Development Officer Paul Gineste brings 25 years of experience in clinical development and strategy with leading international pharmaceutical and biotech companies.Recently, Paul served as Vice President, Clinical Operations at Abivax, where he led the development of drug candidates from discovery through global Phase 3 programs. Paris, France, January 4, 2024 - Evexta Bio SA, a clinical-stage biotechnology company focused on developing first-in-class therapies in oncology, announces the appointment of Paul Gineste as Chief Development Officer (CDO), effective January 1, 2024. Paul is an experienced senior executive with a track record of successful achievements in the Pharma and Biotech Industry. He has worked with leading international pharmaceutical and biotech companies, including as International Clinical Trials Manager at Boehringer Ingelheim, Head of Clinical Research and Development at Altana Pharma, Executive Vice President, Clinical Development at Theravectys, a lentiviral vector spin-off from the Institut Pasteur, and most recently for 9 years as Vice President, Clinical Operations at Abivax, where he led drug candidates from discovery through global Phase 3 programs. Scott Filosi, CEO of Evexta Bio, said: "I am delighted to welcome Paul as the new Chief Development Officer of Evexta Bio. With his extensive track record in the pharmaceutical and biotech industries, Paul is the best suited to lead our clinical development and strategy as our lead candidate, rupitasertib, is expected to enter a phase 2/3 clinical trial in refractory ER+ HER2 metastatic breast cancer.” Paul Gineste, PharmD, CDO of Evexta Bio, added: “I am genuinely pleased to join Evexta Bio and its experienced management team to advance its development strategy and in particular its clinical programs. Evexta Bio has two proprietary therapeutic assets with original mechanisms of action that may address unmet medical needs in multiple cancer indications. I look forward to leading and accelerating their clinical development.” ***** Upcoming opportunity to meet our team: EVEXTA BIO will be in San Francisco, CA, during the JP Morgan's 42nd Annual Healthcare Conference, January 8-11, 2024. Contact us today to arrange a meeting with our executives in San Francisco: Scott Filosi, Chief Executive Officer, and Dominique Bridon, Chief Scientific Officer. About Evexta Bio (https://www.evextabio.com) Evexta Bio, formerly Diaccurate, is a biopharmaceutical company revolutionizing cancer treatment with potential first-in-class therapies with unique mechanisms of action for combating tumor resistance . Now in the clinic, the French biotech is currently developing two proprietary therapeutic assets across several indications: Rupitasertib, formerly DIACC3010, a first-in-class S6K inhibitor addressing tumor resistance while blocking the compensatory AKT feedback loop. The oral anti-tumor agent is expected to enter phase 2/3 clinical trial in refractory ER+ HER2- metastatic breast cancer. EVX-020, formerly DIACC2020, an antibody-drug conjugate program using a first-in-class KIF20A kinesin inhibitor as payload in hematological and solid tumors. Founded by Truffle Capital, Evexta Bio has forged alliances with leaders in academia and industry, including CNRS, Paoli-Calmettes Institute (Marseille, France) and Merck KGaA (Darmstadt, Germany). The company is supported by seasoned management team, board of directors and medical advisory board. Contacts ATCG PARTNERSMarie Puvieux+33 (0)6 10 54 36 72presse@atcg-partners.com Attachment PR in English

Diaccurate Announces the Appointment of Scott Filosi as EVEXTA BIOCEO and Corporate Name Change to Evexta Bio Scott Filosi brings more than 30 years of experience in market access and commercialization of innovative medicines at a global level. New name reflects the company's focus on its innovative portfolio of drug candidates that push the boundaries of precision oncology. Paris, France, November 6, 2023 - Diaccurate SA, a clinical-stage biotechnology company focused on developing targeted therapeutics in oncology, - announces the appointment of Scott Filosi as Chief Executive Officer (CEO), effective November 6, 2023. The company changes name to Evexta Bio, effective immediately. Dominique Bridon, former CEO, is appointed Chief Scientific Officer, and will remain as an executive and Board Member. Scott is an experienced executive leader with an outstanding track record in the pharmaceutical and biotechnology sector and as CEO. Scott brings more than 30 years of experience where he has put on the market more than 20 innovative medicines. Scott served as CEO of Luzsana Bio and Mirror Bio where he helped to advance key clinical programs, raise capital and advance strategic imperatives. Prior to his CEO roles, Scott was successively global Senior Vice President Market Access and Pricing and Chief Commercial Officer US for Merck KGaA successfully launching multiple oncology assets and indications. He brings diverse experience in sales, marketing, market access, pricing, operations and business development with organizations including UCB, J&J and Boehringer-Ingelheim. The Annual General Meeting also approved the change of company name to Evexta Bio. designed to better represent the company’s ability to advance rupitasertib through Phase 2/3 development, and to collaborate with partners for further development and commercialization. Along with the new name, the Company has adopted a new logo and is refreshing its corporate website to reflect the company’s strategy moving forward. Visit to learn more. Alain Chevallier, Chairman of the Board of Evexta Bio, commented:“The Board of Directors warmly welcomes Scott as the new CEO of Evexta Bio. Given his extensive international management experience in bringing successfully oncology drugs on the market, Scott is uniquely qualified to lead Evexta Bio's strategic development. He brings a unique set of skills, perspectives, and network to lead Evexta Bio into this new stage. I warmly thank Dominique for leading, during his tenure as CEO the shift of the company from a preclinical start-up to a late clinical stage biotech. I am pleased that he will continue to bring its tremendous scientific expertise to Evexta Bio as Chief Scientific Officer.” Scott Filosi, new CEO and Board Member of Evexta Bio,added: "I am thrilled to join Evexta Bio and its impressive team in a leadership position to advance its development strategy, and in particular, its clinical programs, both alone and in partnerships. I would like to thank Dominique for his dedication and look forward to building together on his achievements.” Dominique Bridon, PhD, CSO of Evexta Bio, said:“I am delighted to have Scott as the new CEO of Evexta Bio. With his impressive track record in the pharmaceutical and biotech industries, I believe Scott is the right person to lead the company through this important phase of development and partnering. I look forward to continuing to provide my scientific support to Evexta Bio.” ***** About Evexta Bio ( ) Evexta Bio, formerly Diaccurate, is a biopharmaceutical company exploring the new frontiers of oncology in search of daring novel therapeutic approaches with the potential to save lives. Now in the clinic, the French biotech is currently developing two proprietary therapeutic assets with novel mechanisms of action across several indications: Rupitasertib, formerly DIACC3010, an optimized S6K inhibitor with efficient AKT1/AKT3 control of feed-back loop. The oral anti-tumor agent is expected to enter phase 2/3 clinical trial in refractory ER+ HER2- metastatic breast cancer. EVX020, formerly DIACC2020, an antibody-drug conjugate program using a sole-in-class KIF20A kinesin inhibitor as payload in hematological and solid tumors. Founded by Truffle Capital, Evexta Bio has forged alliances with leaders in academia and industry, including CNRS, Paoli-Calmettes Institute (Marseille, France) and Merck KGaA (Darmstadt, Germany). The company is supported by seasoned management team, board of directors and medical advisory board. Contacts ATCG PARTNERS Marie Puvieux +33 (0)9 52 78 85 08 presse@atcg-partners.com Attachment PR in English

MILAN--(BUSINESS WIRE)-- Sibylla Biotech today announces the appointment of Dominique Bridon, Ph.D., as Executive Chairman of its Board of Directors. Dr. Bridon brings more than 30 years of experience in operations as well as research and development in the pharmaceutical and biotechnology sectors. As an expert in implementing AI-based technologies for drug development and with a broad knowledge base in precision oncology, Dr. Bridon has successfully led drug discovery efforts from conception to clinical development. Joining Sibylla, Dr. Bridon will contribute his expertise and lead the Board as Sibylla expands its proprietary pipeline of innovative protein degraders. “Dominique’s background in advancing new therapeutics, his proven track record as a successful biotech entrepreneur and his passion for science that is a great fit for Sibylla’s culture will be highly valuable as we enter the next stages of our corporate growth,” commented Lidia Pieri, Co-Founder and Chief Executive Officer of Sibylla Biotech. “We are leveraging our protein folding simulation platform to build out our pipeline starting with our lead candidate designed to degrade Cyclin D1, a protein that is amplified and overexpressed in a range of cancers but remains elusive to drug targeting efforts. During this period of progressive expansion in our preclinical activities, Dominique's engagement will be instrumental.” “Sibylla Biotech’s cutting-edge PPI-FIT technology has the potential to address previously undruggable targets across many indications and redefine the protein degradation landscape,” said Dr. Dominique Bridon. “I look forward to working with the team and the Board to continue advancing Sibylla’s highly-differentiated approach while driving the further development of its lead candidate in oncology.” Dr. Dominique Bridon has served as CEO of Diaccurate SAS, a clinical-stage biopharmaceutical company developing precision oncology therapies, since 2020. Prior to this, Dr. Bridon held a range of senior positions at various pharmaceutical and biotechnology companies, including Senior Vice President and acting CSO, Discovery and Innovation at Ipsen, a leader in peptide and protein therapeutics. Dr. Bridon is the scientific co-founder of several biotechnology companies and is an inventor and co-inventor of more than 50 patents and patent applications. He is also a member of the Scientific Boards of Jalon Therapeutics, Concarlo Therapeutics, and EpiVax Therapeutics. Dr. Bridon holds a Ph.D. in Organic Chemistry from the University of Paris XI and completed a post-doctoral research position at the University of California, Berkeley. He obtained an M.S. in Chemical Engineering from the École Nationale Supérieure de Chimie and an M.S. in Polymer Sciences from the University of Clermont-Ferrand. About Sibylla Biotech Sibylla is disrupting the protein degradation landscape by applying a novel mechanism of action that interferes with protein folding and thereby suppresses the expression of a disease-relevant protein. Through its protein folding simulation technology platform, Pharmacological Protein Inactivation by Folding Intermediate Targeting (PPI-FIT), Sibylla identifies relevant and previously inexplorable folding intermediates for protein targets that are currently considered undruggable in their native state. The company is developing a proprietary pipeline of small molecule folding interfering degraders (FIDs) that can address a range of therapeutic areas. For further information: View source version on businesswire.com: Contacts Sibylla Biotech Lidia Pieri +39 347 6499534 lidia.pieri@sibyllabiotech.it Trophic Communications Valeria Fisher or Dr. Alison Opalko +49 175 80 41 816 or +49 151 54041130 sibylla@trophic.eu Source: Sibylla Biotech View this news release online at: